VIP demonstrates potent anti-inflammatory and immunosuppressive properties through regulatory T-cell generation and dendritic cell tolerization, positioning it as a novel autoimmune therapy — from arthritis to multiple sclerosis.
Key findingVIP generates regulatory T-cells, tolerizes dendritic cells, and suppresses Th1/Th17 inflammatory pathways, providing a comprehensive anti-autoimmune
What the researchers found
VIP generates regulatory T-cells, tolerizes dendritic cells, and suppresses Th1/Th17 inflammatory pathways, providing a comprehensive anti-autoimmune mechanism applicable to rheumatoid arthritis, MS, type 1 diabetes, and transplant rejection.
Why it matters
Relevant for neuropeptides, inflammation, immune-function.
How the study worked
review study on neuropeptides, inflammation.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.
Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii70-6
Citation
Gonzalez-Rey, Elena; Anderson, Per; Delgado, Mario. (2007). Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.. Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii70-6.